

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C07D 491/22, A61K 31/40, 31/435, C07D 451/00 // (C07D 491/22, 307:00, 221:00, 221:00, 209:00) (C07D 491/22, 307:00, 221:00, 209:00, 209:00)	A1	(11) International Publication Number: WO 97/41125 (43) International Publication Date: 6 November 1997 (06.11.97)												
(21) International Application Number: PCT/EP97/01899 (22) International Filing Date: 15 April 1997 (15.04.97) (30) Priority Data: <table border="0" style="width: 100%;"><tr><td style="width: 30%;">9608850.5</td><td style="width: 40%;">30 April 1996 (30.04.96)</td><td style="width: 30%;">GB</td></tr><tr><td>9608828.1</td><td>30 April 1996 (30.04.96)</td><td>GB</td></tr><tr><td>9608851.3</td><td>30 April 1996 (30.04.96)</td><td>GB</td></tr><tr><td>9608852.1</td><td>30 April 1996 (30.04.96)</td><td>GB</td></tr></table> (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): GASTER, Laramie, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: GARRETT, Michael; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		9608850.5	30 April 1996 (30.04.96)	GB	9608828.1	30 April 1996 (30.04.96)	GB	9608851.3	30 April 1996 (30.04.96)	GB	9608852.1	30 April 1996 (30.04.96)	GB	(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
9608850.5	30 April 1996 (30.04.96)	GB												
9608828.1	30 April 1996 (30.04.96)	GB												
9608851.3	30 April 1996 (30.04.96)	GB												
9608852.1	30 April 1996 (30.04.96)	GB												
(54) Title: SPIROAZABICYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE (57) Abstract Novel azabicyclic derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments are disclosed.														

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

SPIROAZABICYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE

The present invention relates to novel azabicyclic derivatives, processes for their preparation, and pharmaceutical compositions containing them.

5 EPA 0 533 266/7/8 disclose a series of benzanilide derivatives which are said to possess 5HT_{1D} receptor antagonist activity. PCT/EP/95/04889 discloses further 5HT_{1D} receptor antagonists having a spiropiperidine structure. These compounds are said to be of use in the treatment of various CNS disorders. The 5HT_{1D} receptor has now been reclassified as the 5HT_{1B} receptor (P.R Hartig et al Trends in Pharmacological Science, 10 1996, 17, 103 - 105).

A structurally distinct class of compounds have now been discovered and have been found to exhibit 5HT_{1B} receptor antagonist activity. In a first aspect, the present invention therefore provides a compound of formula (I) or a salt or N-oxide thereof:



in which

20 P¹ and P² are independently phenyl, bicyclic aryl, a 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur, or a bicyclic heterocyclic ring containing one to three heteroatoms selected from oxygen, nitrogen or sulphur;

R¹ is hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, COC₁₋₆alkyl, C₁₋₆alkoxy, hydroxy, 25 hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, acyl, nitro, trifluoromethyl, cyano, SR⁹, SOR⁹, SO₂R⁹, SO₂NR¹⁰R¹¹, CO₂R¹⁰, NR¹⁰SO₂R¹¹, CONR¹⁰R¹¹, CO₂NR¹⁰R¹¹, CONR¹⁰(CH₂)_pCO₂R¹¹, (CH₂)_pNR¹⁰R¹¹, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹¹, (CH₂)_pCO₂C₁₋₆alkyl, CO₂(CH₂)_pOR¹⁰, CONHNR¹⁰R¹¹, NR¹⁰R¹¹, N=CNR⁹NR¹⁰R¹¹, NR¹⁰CO₂R¹¹, 30 NR¹⁰CO(CH₂)_pNR¹⁰R¹¹, NR¹⁰CONR¹⁰R¹¹, CR¹⁰=NOR¹¹, CNR¹⁰=NOR¹¹, or NR¹²COR¹³ where R⁹, R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆alkyl, p is 1 to 4, R¹² is hydrogen, C₁₋₆alkyl or together with R^{2'} forms a group (CH₂)_k where k is 2, 3 or 4 and R¹³ is hydrogen, C₁₋₆alkyl or optionally substituted aryl; or R¹ is an optionally

substituted 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;

R^2 and R^3 are independently hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl,

C_{3-6} cycloalkenyl, C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, C_{1-6} alkylOC C_{1-6} alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO_2R^{10} , $CONR^{10}R^{11}$, $NR^{10}R^{11}$ where R^{10} and R^{11} are independently hydrogen or C_{1-6} alkyl, or R^2 and R^3 together form a group $-(CH_2)_r-R^{14}-(CH_2)_s-$ where R^{14} is O, S, CH_2 or NR^{15} where R^{15} is hydrogen or C_{1-6} alkyl and r and s are independently 0, 1 or 2;

R is a group $-DR^6-C(=B)-$ or $-C(=B)DR^6-$;

B is oxygen or sulphur;

D is nitrogen or a CH group;

R^6 is hydrogen or C_{1-6} alkyl and R^7 is hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy or halogen or R^6 together with R^7 forms a group $-A-$ where A is $(CR^{16}R^{17})_t$ where t is 2, 3 or 4 and R^{16} and R^{17} are independently hydrogen or C_{1-6} alkyl or A is $(CR^{16}R^{17})_u-J$ where u is 0, 1, 2 or 3 and J is oxygen, sulphur, $CR^{16}=CR^{17}$, $CR^{16}=N$, $=CR^{16}O$, $=CR^{16}S$ or $=CR^{16}-NR^{17}$;

E is oxygen, $CR^{18}R^{19}$ or NR^{20} where R^{18} , R^{19} and R^{20} are independently hydrogen or C_{1-6} alkyl or E is $S(O)_v$ where v is 0, 1 or 2;

G is $C=O$ or $CR^{21}R^{22}$ where R^{21} and R^{22} are independently hydrogen or C_{1-6} alkyl; and

X is an optionally substituted 7,6, 7,5, 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulphur.

C_{1-6} alkyl groups, whether alone or as part of another group, may be straight chain or branched. As used herein the term aryl includes phenyl and naphthyl. Heteroaryl groups include thienyl, furyl, pyridyl, pyrimidyl and pyrazinyl groups. Optional substituents for aryl and heteroaryl groups include those groups listed above for R^2/R^3 .

Suitably P^1 and P^2 are independently selected from phenyl, bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur, or a bicyclic heterocyclic ring containing one to three heteroatoms selected from oxygen, nitrogen or sulphur. Examples of bicyclic aryl groups include naphthyl. Examples of bicyclic heterocyclic rings include quinoline, isoquinoline, benzofuran and benzothiophene. Examples of suitable monocyclic heterocyclic rings include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl. Preferably P^1 and P^2 are both phenyl. The P^1 and P^2 groups can be attached to the remainder of the molecule at any suitable points.

Suitably R^1 is hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, COC_{1-6} alkyl,

C₁₋₆alkoxy, hydroxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, acyl, nitro, trifluoromethyl, cyano, SR⁹, SOR⁹, SO₂R⁹, SO₂NR¹⁰R¹¹, CO₂R¹⁰, NR¹⁰SO₂R¹¹, CONR¹⁰R¹¹, CO₂NR¹⁰R¹¹, CONR¹⁰(CH₂)_pCO₂R¹¹, (CH₂)_pNR¹⁰R¹¹, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹¹, (CH₂)_pCO₂C₁₋₆alkyl, 5 CO₂(CH₂)_pOR¹⁰, CONHNR¹⁰R¹¹, NR¹⁰R¹¹, N=CNR⁹NR¹⁰R¹¹, NR¹⁰CO₂R¹¹, NR¹⁰CO(CH₂)_pNR¹⁰R¹¹, NR¹⁰CONR¹⁰R¹¹, CR¹⁰=NOR¹¹, CNR¹⁰=NOR¹¹, or NR¹²COR¹³ where R⁹, R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆alkyl, p is 1 to 4, R¹² is hydrogen, C₁₋₆alkyl or together with R^{2'} forms a group (CH₂)_k where k is 2, 3 or 4 and R¹³ is hydrogen, C₁₋₆alkyl or optionally substituted aryl; or R¹ is an optionally 10 substituted 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur.

When R¹ is a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur suitable heterocyclic rings include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, 15 isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl. Saturated and partially saturated rings are also within the scope of the invention, in particular rings including an oxo or thioxo moiety such as lactams and thiolactams. The heterocyclic rings can be linked to the remainder of the molecule via a carbon atom or, when present, a nitrogen atom. Suitable substituents for these rings include R² and R³ groups as defined 20 above. Preferably R¹ is optionally substituted 2-oxo-1-pyrrolidinyl group.

Suitably R² and R³ are independently hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, C₁₋₆alkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO₂R⁹, CONR¹⁰R¹¹, NR¹⁰R¹¹ where R⁹, R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆alkyl, or R² and 25 R³ together form a group -(CH₂)_r-R¹⁴-(CH₂)_s- where R¹⁴ is O, S, CH₂ or NR¹⁵ where R¹⁵ is hydrogen or C₁₋₆alkyl and r and s are independently 0, 1 or 2.

Preferably R² is C₁₋₆ alkyl. Preferably the R² groups is ortho with respect to the linkage between the P¹ and P² rings. Most preferably R² is methyl and R³ is hydrogen.

Suitably R is a group -DR⁶-C(=B)- or -C(=B)DR⁶-, preferably R is -C(=B)DR⁶-. 30

Suitably B is oxygen or sulphur. Preferably B is oxygen.

Suitably D is nitrogen or a CH group. Preferably D is nitrogen.

Suitably R⁶ is hydrogen or C₁₋₆alkyl and R⁷ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy or halogen or R⁶ together with R⁷ forms a group -A- where A is (CR¹⁶R¹⁷)_t where t is 2, 3 or 4 and R¹⁶ and R¹⁷ are independently hydrogen or C₁₋₆alkyl or A is (CR¹⁶R¹⁷)_u-J 35 where u is 0, 1, 2 or 3 and J is oxygen, sulphur, CR¹⁶=CR¹⁷, CR¹⁶=N, =CR¹⁶O,

$=\text{CR}^{16}\text{S}$ or $=\text{CR}^{16}\text{-NR}^{17}$. Preferably R^6 together with R^7 forms a group -A- where A is $(\text{CR}^{16}\text{R}^{17})_t$ where t is 2 and R^{16} and R^{17} are both hydrogen.

Suitably E is oxygen, $\text{CR}^{18}\text{R}^{19}$ or NR^{20} where R^{18} , R^{19} and R^{20} are independently hydrogen or C_{1-6} alkyl or E is $\text{S}(\text{O})_v$ where v is 0, 1 or 2. Preferably E is oxygen.

Suitably G is C=O or $\text{CR}^{21}\text{R}^{22}$ where R^{21} and R^{22} are independently hydrogen or C_{1-6} alkyl. Preferably G is CH_2 .

Suitably X is a 7,6, 7,5, 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulphur.

Examples of such groups include tropane, isotropane, quinuclidine, isoquinuclidine, granatane, oxa-granatane, thia-granatane, aza-granatane, quinolizidine, indolizidine, 1-azabicyclo[3.2.1]octane, 1-azabicyclo[3.3.1]nonane, iso-granatane, oxaiso-granatane, and thiaisogranatane rings. It will be appreciated that the group X is attached to the rest of the molecule by a spiro-linkage. The 5, 6 or 7-membered rings of the group X can form the spiro-linkage. Optional substituents for such ring systems, which can be present on carbon and nitrogen atoms, include C_{1-6} alkyl such as methyl. More than one substituent can be present. Preferably X is indolizidine, 1-azabicyclo[3.3.1]nonane or tropane.

Preferred compounds of the invention include:

5-[2'-Methyl-4'-(2-oxo-1-pyrrolidinyl)biphenyl-4-carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,7'-indolizidine],

5-[2'-Methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-(1-azabicyclo[3.3.1]nonane)],

5-[2'-Methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]-8'-methyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,3'-tropane],


or pharmaceutically acceptable salts thereof.

Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and the mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the invention.


In a further aspect the present invention provides a process for the preparation of a compound of formula (I) which comprises:

(a) for compounds of formula (I) where D is nitrogen, B is oxygen reaction of a compound of formula (II):



(II)

in which P¹, P², R¹, R², R^{2'} and R³ are groups as defined in formula (I) or protected derivatives thereof with a compound of formula (III):



(III)

wherein R⁷, E, G and X are groups as defined in formula (I) or protected derivatives thereof, and R²³ and R²⁴ contain the appropriate functional group(s) necessary to form the R moiety, and optionally thereafter in any order:

- removing any protecting groups,
- converting a compound of formula (I) into another compound of formula (I),
- forming a pharmaceutically acceptable salt.

Suitably one of R²³ or R²⁴ is an activated carboxylic acid derivative, such as an acyl halide or acid anhydride, and the other is an amine group. Activated compounds of formulae (II) or (III) can also be prepared by reaction of the corresponding carboxylic acid with a coupling reagent such as carbonyldiimidazole, dicyclohexylcarbodiimide or diphenylphosphorylazide. Preferably R²³ or R²⁴ is a group COL where L is halo, particularly chloro.

A compound of formulae (II) and (III) are typically reacted together in an inert organic solvent such as DMF, THF or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine, pyridine or alkali metal hydroxide.

Compounds of formulae (II) and (III) can be prepared from the corresponding carboxylic acids using standard procedures. For example acid chlorides can be prepared by reaction with phosphorous pentachloride, oxalyl chloride or thionyl chloride. Acid anhydrides can

be prepared by reaction with a suitable acid anhydride, for example trifluoroacetic anhydride.

Alternatively L is an ester forming group such that the resulting esters of formula (III) can be reacted with compounds of formula (II) in the presence of an organo-
5 aluminium reagent such as trimethylaluminium. Such a reaction is typically carried out in the presence of an inert solvent such as toluene.

Intermediate compounds of formula (II) and (III) can be prepared using standard procedures known in the art. Certain intermediate compounds of formula (II) and (III) are novel and form a further aspect of the invention.

10 It will be appreciated to those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures. Standard protection and deprotection techniques can be used such as those described in Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981). For example, primary amines can be protected as phthalimide, benzyl, benzyloxycarbonyl or trityl derivatives.

15 Carboxylic acid groups can be protected as esters. Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection is achieved using standard conditions.

5HT_{1B} receptor antagonists, and in particular the compounds of the present invention, are expected to be of use in the treatment of CNS disorders such as mood
20 disorders, including depression, seasonal affective disorder and dysthymia; anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders and age-associated memory impairment; and disorders of eating behaviours, including anorexia nervosa and bulimia nervosa. Other
25 CNS disorders include motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.

5HT_{1B} receptor antagonists, and in particular compounds of the present invention, may also be of use in the treatment of endocrine disorders such as hyperprolactinaemia, in
30 the treatment of vasospasm (particularly in the cerebral vasculature) and hypertension, as well as disorders in the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction and hypothermia.

Therefore, the present invention provides a compound of general formula (I) or a
35 physiologically acceptable salt or solvate thereof for use in therapy.

The present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.

5 In another aspect the invention provides the use of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of the aforementioned disorders.

10 In a further aspect the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.

In particular the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.

15 It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents.

The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable
25 compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

30 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired,
35 conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following examples illustrate the invention.

Description 1**Ethyl 1,2,3,5,6,8a-hexahydroindolizine-7-carboxylate**

5 The procedure of *Chem. Pharm. Bull.* 1980, 28, 2783 was followed. Chromatography of the crude product on silica, eluting with 0-10% methanol in dichloromethane, gave the title compound.

¹H NMR (200 MHz, CDCl₃) δ (ppm): 6.91 (d, 1H), 4.20 (q, 2H), 3.47 (m, 1H), 3.02 (m, 1H), 2.80 (m, 3H), 2.38 (m, 2H), 2.08 (m, 1H), 1.84 (m, 2H), 1.58 (m, 1H), 1.30 (t, 3H).

10

Description 2**1,2,3,5,6,8a-Hexahydroindolizine-7-methanol**

15 Ethyl 1,2,3,5,6,8a-hexahydroindolizine-7-carboxylate (D1, 0.89g, 4.6 mmol) was stirred under Ar in dry THF (50 ml) as lithium aluminium hydride (0.35g, 9.2 mmol) was added portionwise. After 30 min, the reaction was worked up by successive addition of water (0.35 ml), 10% NaOH (0.35 ml) and water (1.05 ml). The solid was filtered off, and the filtrate was evaporated to yield the title compound (0.67g, 97%) as a brown oil.

20 ¹H NMR (250 MHz, CDCl₃) δ (ppm): 5.67 (s, 1H), 3.96 (s, 2H), 2.5-3.9 (m, 6H), 1.2-2.3 (m, 6H).

Description 3**1-Acetyl-6-bromo-5-[(1,2,3,5,6,8a-hexahydroindolizin-7-yl)methoxy]indoline**

25

1-Acetyl-6-bromo-5-hydroxyindoline (*Tetrahedron* 1973, 29(8), 1115) (1.24g, 4.8 mmol), 1,2,3,5,6,8a-hexahydroindolizine-7-methanol (D2, 0.74g, 4.8 mmol) and triphenylphosphine (1.27g, 4.8 mmol) were stirred under Ar in dry THF (50 ml) as diethyl azodicarboxylate (0.76ml, 4.8 mmol) was added dropwise. The mixture was stirred for 30 1h, diluted with ethyl acetate, and extracted with dil. HCl. The extract was basified with potassium carbonate, and extracted with chloroform. This extract was dried (Na₂SO₄) and evaporated to give a dark oil. Further treatment of this oil as above with the phenol, triphenylphosphine and diethyl azodicarboxylate caused reaction to proceed further. Chromatography on silica, eluting with 0-20% methanol/dichloromethane, gave the title 35 compound (0.25g, 13%) as a brown gum.

¹H NMR (200 MHz, CDCl₃) δ (ppm): 8.40 (s, 1H), 6.73 (s, 1H), 5.82 (s, 1H), 4.41 (s, 2H), 4.03 (t, 2H), 3.12 (t, 2H), 2.6-3.3 (m, 5H), 2.18 (s, 3H), 1.2-2.5 (m, 6H).

Description 4

5 5-Acetyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,7'-indolizidine]

1-Acetyl-6-bromo-5-[(1,2,3,5,6,8a-hexahydroindolizin-7-yl)methoxy]indoline (D3) (0.118g, 0.3 mmol) and α,α'-azoisobutyronitrile (0.04g) were stirred at reflux under Ar in benzene (40 ml) as tributyltin hydride (0.24 ml, 0.9 mmol) was added dropwise in benzene
 10 (10 ml) over 10 min. The mixture was stirred at reflux for 6h, cooled, and extracted with dil. HCl. The extract was basified with saturated K₂CO₃, and extracted with chloroform. The organic extract was dried (Na₂SO₄) and evaporated to give the title compound (0.073g, 77%) as a brown gum. NMR showed a mixture of two isomers.

15 ¹H NMR (250 MHz, CDCl₃) δ (ppm): 8.44 (s) and 8.02 (s) (1H), 6.57 (s) and 6.54 (s) (1H), 4.12 (s, 2H), 3.9-4.4 (m, 2H), 2.8-3.2 (m, 4H), 2.15 (s) and 2.11 (s) (3H), 1.0-2.7 (m, 11H).

Description 5

20 2,3,6,7-Tetrahydrospiro[furo[2,3-f]indole-3,7'-indolizidine]

5-Acetyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,7'-indolizidine] (D4, 0.079g, 0.25 mmol) was stirred at reflux in a mixture of ethanol (10 ml) and 5M HCl (20 ml) for 2.5h. The mixture was concentrated to small volume, basified with 10% Na₂CO₃ and extracted
 25 with chloroform. The extract was dried (Na₂SO₄) and evaporated to give the title compound (0.058g, 85%) as a brown gum. NMR showed 2 isomeric components.

¹H NMR (200 MHz, CDCl₃) δ (ppm): 6.79 (s), 6.57 (s), 6.53 (s) and 6.37 (s) (2H), 4.07 (s, 2H), 3.46 (m, 2H), 2.6-3.2 (m, 4H), 0.8-2.6 (m, 12H).

30

Description 6

4-Trifluoromethanesulphonyloxy-1-azabicyclo[3.3.1]non-3-ene

A stirred solution of diisopropylamine (1.7ml, 0.012 mole) in dry THF (20 ml) at -65°C
 35 under argon was treated with 1.6M n-butyllithium in hexane (6.87 ml, 0.011 mole) and kept for 20 minutes, then treated dropwise over 10 minutes with a solution of 1-

azabicyclo[3.3.1]nonan-4-one (1.4g, 0.10 mole) in THF (20 ml). The mixture was stirred at -70°C for 1.25h, then treated with a solution of N,N-bis(trifluoromethanesulphonyl) aniline (3.93g, 0.011 mole) in THF (20 ml) and the reaction mixture allowed to warm to room temperature and stir for 20 h. The solution was concentrated *in vacuo* and the residue chromatographed on neutral alumina eluting initially with 1:1 ether/60-80 petrol and increasing polarity to neat ether, then neat ethyl acetate to afford the title compound as a yellow oil (2.5g), contaminated with some aniline product.

¹H NMR (250 MHz, CDCl₃) δ (ppm): 6.00 (t, 1H), 3.80 (d, 1H), 3.26 (dd, 1H), 3.11 (d, 1H), 3.15-2.85 (m, 3H), 2.40 (br s, 1H), 1.95-1.60 (m, 3H), 1.57-1.34 (m, 1H).

Description 7

Methyl 1-azabicyclo[3.3.1]non-3-en-4-yl carboxylate

A stirred solution of 4-trifluoromethanesulphonyloxy-1-azabicyclo[3.3.1]non-3-ene (D6, 2.5g, ≤ 0.0092 mole) in methanol (15 ml) was treated with triethylamine (2.6 ml, 0.018 mole) and triphenylphosphine (135 mg, 0.52 mmole), then carbon monoxide was bubbled through the stirring solution for 5 minutes, before palladium (II) acetate (60 mg, 0.27 mmole) was added. The reaction flask was sealed under a carbon monoxide balloon and stirred at 25°C for 20 h. The mixture was filtered through a pad of kieselguhr and the filtrate was concentrated *in vacuo*. The residue was treated with 2M HCl acid (30 ml) and ethyl acetate (30 ml), then shaken well and the acid layer isolated, basified with solid K₂CO₃ and extracted with chloroform. The extract was dried (Na₂SO₄) and concentrated *in vacuo* to afford the title compound as a yellow oil (0.99g, 54%).

¹H NMR (200 MHz, CDCl₃) δ (ppm): 7.22 (t, 1H), 3.78 (dt, 1H), 3.74 (s, 3H), 3.25 (dd, 1H), 3.10-2.88 (m, 3H), 2.80 (br d, 1H), 2.64 (br s, 1H), 1.80-1.40 (m, 3H), 1.30-1.18 (m, 1H).

Description 8

1-Azabicyclo[3.3.1]non-3-en-4-methanol

The title compound was prepared from methyl 1-azabicyclo[3.3.1]non-3-en-4-yl carboxylate (D7) using a similar procedure to Description 2 as a pale yellow oil (100%).

¹H NMR (250 MHz, CDCl₃) δ (ppm): 5.89 (m, 1H), 4.02 (d, 2H), 3.68 (dt, 1H), 3.20-2.78 (m, 5H), 2.50-2.28 (m, 1H), 2.10 (br s, 1H), 1.80-1.54 (m, 3H), 1.35-1.18 (m, 1H).

Description 9

5 1-Acetyl-5-(1-azabicyclo[3.3.1]non-3-en-4-yl)methoxy-6-bromo-2,3-dihydro-1H-indole

The title compound was prepared from 1-azabicyclo[3.3.1]non-3-en-4-methanol (D8) using a similar procedure to Description 3 as a brown oil (100%) contaminated with some
10 DEAD product.

¹H NMR (250 MHz, CDCl₃) δ (ppm): 8.44 (s, 1H), 6.75 (s, 1H), 6.08 (br s, 1H), 4.42 (s, 2H), 4.05 (t, 2H), 3.72 (br d, 1H), 3.15 (t, 2H), 3.20-2.80 (m, 5H), 2.25 (br s, 1H), 2.20 (s, 3H), 1.90-1.60 (m, 3H), 1.35-1.20 (m, 1H).

15

Description 10

5-Acetyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-(1-azabicyclo[3.3.1]nonane)]

The title compound was prepared from 1-acetyl-5-(1-azabicyclo[3.3.1]non-3-en-4-yl)methoxy-6-bromo-2,3-dihydro-1H-indole (D9) by a similar procedure to Description 4 using toluene as solvent. The two isomers (2:1 ratio) formed around the spirocyclic junction were separated by column chromatography on silica gel eluting with 0-15% methanol/chloroform.

25 Higher rf isomer (D10a, 15%) - ¹H NMR (250 MHz, CDCl₃) δ (ppm): 7.95 (s, 1H), 6.67 (s, 1H), 4.20-3.95 (m, 4H), 3.58-3.32 (m, 2H), 3.30-2.75 (m, 6H), 2.47-2.33 (m, 1H), 2.25-1.80 (m, 4H), 2.19 (s, 3H), 1.68-1.42 (m, 2H).

Lower rf isomer (D10b, 18%) - ¹H NMR (250 MHz, CDCl₃) δ (ppm): 8.55 (s, 1H), 6.63 (s, 1H), 4.55 (d, 1H), 4.10-3.95 (m, 3H), 3.65-3.50 (m, 2H), 3.25-2.97 (m, 5H), 2.90 (br d, 1H), 2.20 (s, 3H), 2.15-1.65 (m, 5H), 1.55-1.38 (m, 2H).
30

Descriptions 11a and 11b

2,3,6,7-Tetrahydrospiro[furo[2,3-f]indole-3,4'-(1-azabicyclo[3.3.1]nonane)]

35 The two isomers of 5-acetyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-(1-azabicyclo[3.3.1]nonane)] (D10a and D10b) were separately hydrolysed to give the two

isomers of the title compound (D11a and D11b) following a similar procedure to Description 5.

Higher rf isomer (D11a, 83%) - ^1H NMR (250 MHz, CDCl_3) δ (ppm): 6.67 (s, 1H), 6.36 (s, 1H), 4.18-3.93 (m, 2H), 3.70-2.75 (m, 10H), 2.45-2.30 (m, 1H), 2.25-1.80 (m, 4H), 1.70-1.40 (m, 2H).

Lower rf isomer (D11b, 88%) - ^1H NMR (250 MHz, CDCl_3) δ (ppm): 6.90 (s, 1H), 6.65 (s, 1H), 4.50 (d, 1H), 3.94 (d, 1H), 3.65-3.40 (m, 4H), 3.25-2.80 (m, 7H), 2.15-1.30 (m, 7H).

Description 12

1-(4-Bromo-3-methylphenyl)pyrrolidin-2-one

A stirred solution of 4-bromo-3-methylaniline (50.3g, 0.27 mole) and triethylamine (41.4 ml, 0.30 mole) in THF (250 ml) at 0°C under argon was treated dropwise with 4-chlorobutyryl chloride (33.4 ml, 0.30 mole). The mixture was stirred for 1 hour at $0-5^\circ\text{C}$, then potassium t-butoxide (82.5g, 0.74 mole) was added portionwise over 20 minutes, maintaining temperature below 25°C . The reaction mixture was stirred at 25°C for a further 2.5 hrs, then treated with water (100 ml), followed after 0.25 hrs with 10% Na_2CO_3 solution and then extracted with ethyl acetate. The extract was washed with water, dil. HCl acid, then brine, dried (Na_2SO_4) and concentrated *in vacuo* to afford the title compound as a pale yellow solid (61.6g, 89%).

^1H NMR (250 MHz, CDCl_3) δ (ppm): 7.54 (d, 1H), 7.48 (d, 1H), 7.30 (dd, 1H), 3.82 (t, 2H), 2.58 (t, 2H), 2.40 (s, 3H), 2.16 (quintet, 2H).

Description 13

2'-Methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carboxylic acid

A stirred mixture of 1-(4-bromo-3-methylphenyl)pyrrolidin-2-one (D12, 50g, 0.20 mole) and 4-boronobenzoic acid (32g, 0.20 mole) in DME (500 ml) was treated with a solution of sodium carbonate (94g, 0.88 mole) in water (500 ml), then de-gassed by bubbling argon through for 0.25 hrs. Tetrakis (triphenylphosphine)palladium (0) (5g) was added and the mixture heated under reflux for 22 hours, then allowed to cool and concentrated *in vacuo* to approx. 50% volume. The aqueous residue was diluted with water to approx. 1000 ml, washed with ethyl acetate, then acidified with conc. HCl acid. The precipitate was filtered

off, washed with water, dried and recrystallised from ethanol to afford the title compound as a cream solid (30.3g, 52%).

¹H NMR (250 MHz, d⁶DMSO) δ (ppm): 8.01 (d, 2H), 7.67-7.58 (m, 2H), 7.49 (d, 2H), 7.25 (d, 1H), 3.86 (t, 2H), 2.52 (t, 2H), 2.25 (s, 3H), 2.09 (quintet, 2H).

Description 14

Methyl 2'-methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carboxylate

The title compound was prepared from 2'-methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carboxylic acid (D13) by stirring a DMF solution together with iodomethane and potassium carbonate for 3 hours, followed by dilution with water and extraction into ethyl acetate.

15 Description 15

1-Acetyl-6-bromo-5-[(8-methyltrop-2-en-3-yl)methoxy]indoline

Methyl 8-methyltrop-2-en-3-ylcarboxylate (*Acta. Chim. Acad. Sci. Hung.*, 1980, **104** (3), 235-242) underwent lithium aluminium hydride reduction using the method of description 2 (quantitative), and the resulting 8-methyltrop-2-en-3-methanol was converted to the title compound by reaction with 1-acetyl-6-bromo-5-hydroxyindoline (*Tetrahedron* 1973, **29**, (8), 115) using the method of description 3 (53% over both steps), as an orange crystalline material.

¹H NMR (200 MHz, CDCl₃) δ (ppm): 8.41 (s, 1H), 6.7 (s, 1H), 5.92 (br s, 1H), 4.38 (s, 2H), 4.05 (t, 2H), 3.38-3.24 (m, 2H), 3.12 (t, 2H), 2.65-2.49 (m, 1H), 2.32 (s, 3H), 2.19 (s, 3H), 2.13-1.4 (m, 5H).

Description 16

30 5-Acetyl-8'-methyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,3'-tropane]

1-Acetyl-6-bromo-5-[(8-methyltrop-2-en-3-yl)methoxy]indoline (D15) was converted to a mixture of isomers of the title compound using the method of Description 4 (45%).

¹H NMR (200 MHz, CDCl₃) δ (ppm): 7.8 (s, 1H), 6.86 (s, 1H), 4.3 (m, 2H), 4.13 (s, 2H), 4.0 (t, 2H), 3.25 (s, 3H), 3.18-3.0 (m, 2H), 2.89 (t, 2H), 2.65-2.46 (m, 2H), 2.29-2.11 (m, 5H), 2.0-1.8 (m, 2H).

5 Example 1

5-[2'-Methyl-4'-(2-oxo-1-pyrrolidinyl)biphenyl-4-carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,7'-indolizidine]

2'-Methyl-4'-(2-oxo-1-pyrrolidinyl)biphenyl-4-carboxylic acid (D13) (0.076g, 0.25 mmol)
10 was stirred under Ar in dichloromethane (5 ml). Oxalyl chloride (0.03 ml, 0.34 mmol) was added, followed by 1 drop of N,N-dimethylformamide. After stirring for 1h, the mixture was evaporated to dryness, azeotroping with toluene. The residue was dissolved in dichloromethane (1 ml), and a mixture of 2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,7'-indolizidine isomers (D5, 0.056g, 0.21 mmol) in dichloromethane (4 ml) and triethylamine
15 (0.06 ml, 0.43 mmol) were added. After 2h, the mixture was washed with 10% Na₂CO₃, dried (Na₂SO₄) and evaporated. The title compound (0.020g, 16%) was purified by preparative layer chromatography (10% methanol/dichloromethane), followed by precipitation as the hydrochloride salt. NMR showed two isomeric components.

20 ¹H NMR (HCl salt) (400 MHz, d⁶DMSO) δ (ppm): 7.98 (b) and 7.82 (b) (1H), 7.6 (m, 4H), 7.42 (m, 2H), 7.23 (d, 1H), 6.78 (b) and 6.73 (s) (1H), 4.5 (m) and 4.26 (s) (2H), 4.04 (t, 2H), 3.86 (t, 2H), 3.56 (m, 1H), 3.15-3.4 (m, 2H), 3.0 (t, 2H), 2.9-3.15 (m, 2H), 2.50 (t, 2H), 2.27 (s, 3H), 2.10 (m, 2H), 1.6-2.3 (m, 8H).

25 Examples 2a and 2b

5-[2'-Methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-(1-azabicyclo[3.3.1]nonane)]

The two isomers of the title compound were prepared separately from 2'-methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carboxylic acid (D13) and the two separate isomers of 2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-(1-azabicyclo[3.3.1]nonane)] (D11a and D11b) using a similar procedure to Example 1. The hydrochloride salts were obtained as white solids.

30

Higher rf isomer (free base, E2a, 25%) (250 MHz, CDCl₃) δ (ppm): 8.00 (br s, 1H), 7.63-7.46 (m, 4H), 7.40 (d, 2H), 7.25 (d, 1H), 6.72 (s, 1H), 4.30-4.00 (m, 4H), 3.90 (t, 2H), 3.70-2.80 (m, 8H), 2.64 (t, 2H), 2.50-1.90 (m, 7H), 2.32 (s, 3H), 1.75-1.50 (m, 2H).

Lower rf isomer (free base, E2b, 16%) (250 MHz, CDCl₃) δ (ppm): 8.50 (br s, 1H), 7.66-7.30 (m, 7H), 6.69 (s, 1H), 4.65-4.50 (m, 1H), 4.30-3.90 (m, 3H), 3.90 (t, 2H), 3.77-3.50 (m, 1H), 3.30-2.50 (m, 7H), 2.65 (t, 2H), 2.30 (s, 3H), 2.30-1.40 (m, 9H).

Example 3

5-[2'-Methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]-8'-methyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,3'-tropane]


The isomeric mixture of 5-acetyl-8'-methyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,3'-tropane] (D16) was hydrolysed to give an isomeric mixture of 8'-methyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,3'-tropane] using the method of Description 5 (73%).

A solution of 8'-methyl-2,3,6,7-tetrahydrospiro [furo[2,3-f]indole-3,3'-tropane] isomers (50 mg; 0.185 mmol) in toluene (5 ml) was treated at room temperature under argon with trimethylaluminium (2M in toluene) (0.1 ml), followed 10 minutes later by a solution of methyl 2'-methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carboxylate (D14) (57 mg; 0.185 mol) in toluene (5 ml) and the mixture heated to 80°C under argon for 2 h, then overnight at room temperature. The cooled reaction mixture was evaporated *in vacuo*, and chromatographed on silica gel, eluting with methanol and chloroform, to give the title compound as a mixture of isomers (40 mg, 40%). The hydrochloride salt was prepared.

¹H NMR (HCl salt) (400 MHz, d⁶ DMSO) δ (ppm): 10.0 (br s, 1H), 8.35 (br) and 8.19 (br), (1H), 7.72-7.55 (m, 4H), 7.45 (m, 2H), 7.24 (d, 1H), 6.82 (s) and 6.75 (s) (1H), 4.7 (s) and 4.49 (d) (1H), 4.16-4.0 (m, 2H), 3.88 (t, 2H), 3.11-2.98 (m, 2H), 2.77-1.9 (m, 20H).

CLAIMS:

1. A compound of formula (I) or a salt or N-oxide thereof:



(I)

10 in which

P¹ and P² are independently phenyl, bicyclic aryl, a 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur, or a bicyclic heterocyclic ring containing one to three heteroatoms selected from oxygen, nitrogen or sulphur;

- 15 R¹ is hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, COC₁₋₆alkyl, C₁₋₆alkoxy, hydroxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, acyl, nitro, trifluoromethyl, cyano, SR⁹, SOR⁹, SO₂R⁹, SO₂NR¹⁰R¹¹, CO₂R¹⁰, NR¹⁰SO₂R¹¹, CONR¹⁰R¹¹, CO₂NR¹⁰R¹¹, CONR¹⁰(CH₂)_pCO₂R¹¹, (CH₂)_pNR¹⁰R¹¹, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹¹, (CH₂)_pCO₂C₁₋₆alkyl, CO₂(CH₂)_pOR¹⁰,
 20 CONHNR¹⁰R¹¹, NR¹⁰R¹¹, N=CNR⁹NR¹⁰R¹¹, NR¹⁰CO₂R¹¹, NR¹⁰CO(CH₂)_pNR¹⁰R¹¹, NR¹⁰CONR¹⁰R¹¹, CR¹⁰=NOR¹¹, CNR¹⁰=NOR¹¹, or NR¹²COR¹³ where R⁹, R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆alkyl, p is 1 to 4, R¹² is hydrogen, C₁₋₆alkyl or together with R^{2'} forms a group (CH₂)_k where k is 2, 3 or 4 and R¹³ is hydrogen, C₁₋₆alkyl or optionally substituted aryl; or R¹ is an optionally
 25 substituted 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;
 R² and R³ are independently hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, C₁₋₆alkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO₂R¹⁰, CONR¹⁰R¹¹, NR¹⁰R¹¹ where
 30 R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆alkyl, or R² and R³ together form a group -(CH₂)_r-R¹⁴-(CH₂)_s- where R¹⁴ is O, S, CH₂ or NR¹⁵ where R¹⁵ is hydrogen or C₁₋₆alkyl and r and s are independently 0, 1 or 2;
 R is a group -DR⁶-C(=B)- or -C(=B)DR⁶-;
 B is oxygen or sulphur;

D is nitrogen or a CH group;

R⁶ is hydrogen or C₁₋₆alkyl and R⁷ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy or halogen or R⁶ together with R⁷ forms a group -A- where A is (CR¹⁶R¹⁷)_t where t is 2, 3 or 4 and R¹⁶ and R¹⁷ are independently hydrogen or C₁₋₆alkyl or A is (CR¹⁶R¹⁷)_u-J where u is 0, 1, 2 or 3 and J is oxygen, sulphur, CR¹⁶=CR¹⁷, CR¹⁶=N, =CR¹⁶O, =CR¹⁶S or =CR¹⁶-NR¹⁷;

E is oxygen, CR¹⁸R¹⁹ or NR²⁰ where R¹⁸, R¹⁹ and R²⁰ are independently hydrogen or C₁₋₆alkyl or E is S(O)_v where v is 0, 1 or 2;

G is C=O or CR²¹R²² where R²¹ and R²² are independently hydrogen or C₁₋₆alkyl; and

X is an optionally substituted 7,6, 7,5, 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulphur.

2. A compound according to claim 1 in which P¹ is phenyl.

3. A compound according to claim 1 or 2 in which P² is phenyl.

4. A compound according to any one of claim 1 to 3 in which R² is C₁₋₆alkyl and R³ is hydrogen.

5. A compound according to any one of claims 1 to 4 in which R is -C(=B)DR⁶.

6. A compound according to any one of claims 1 to 5 in which B is oxygen.

7. A compound according to any one of claims 1 to 6 in which X is a tropane, isotropane, quinuclidine, quinolizidine, indolizidine, 1-azabicyclo[3.2.1]octane, 1-azabicyclo[3.3.1]nonane, isoquinuclidine, granatane, oxa-granatane, thia-granatane, aza-granatane, iso-granatane, oxaiso-granatane, or thiaisogranatane ring.

8. A compound according to claim 1 which is:

5-[2'-Methyl-4'-(2-oxo-1-pyrrolidinyl)biphenyl-4-carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,7'-indolizidine],


5-[2'-Methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-(1-azabicyclo[3.3.1]nonane)],

5-[2'-Methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]-8'-methyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,3'-tropane],

or a pharmaceutically acceptable salt thereof.


9. A process for the preparation of a compound of formula (I) which comprises:

(a) for compounds of formula (I) where D is nitrogen, B is oxygen reaction of a compound of formula (II):



(II)

- 5 in which P¹, P², R¹, R², R^{2'} and R³ are groups as defined in formula (I) or protected derivatives thereof with a compound of formula (III):



(III)

10

wherein R⁷, E, G and X are groups as defined in formula (I) or protected derivatives thereof, and R²³ and R²⁴ contain the appropriate functional group(s) necessary to form the R moiety, and optionally thereafter in any order:

- 15
- removing any protecting groups,
 - converting a compound of formula (I) into another compound of formula (I),
 - forming a pharmaceutically acceptable salt.
10. A compound according to any one of claims 1 to 8 for use in therapy.
11. A pharmaceutical composition which comprises a compound according to
- 20 any one of claims 1 to 8 in association with a pharmaceutically acceptable carrier or excipient.

INTERNATIONAL SEARCH REPORT

Internaur Application No
PCT/EP 97/01899

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D491/22 A61K31/40 A61K31/435 C07D451/00
/(C07D491/22,307:00,221:00,221:00,209:00),(C07D491/22,307:00,
221:00,209:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 11934 A (SMITHKLINE BEECHAM PLC) 25 April 1996 see claims 1-5,7-9 ---	1-6,9-11
A,P	WO 96 19477 A (SMITHKLINE BEECHAM PLC) 27 June 1996 cited in the application see claims 1,9,10 ---	1-6,10, 11
A	EP 0 564 358 A (ADIR ET COMPAGNIE) 6 October 1993 see page 2, line 41 - line 51; claims 1,17,18 ---	1,10,11
A	EP 0 635 497 A (ADIR ET COMPAGNIE) 25 January 1995 see page 2, line 22 - line 35; claims 1,10,11 ---	1,10,11
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 June 1997

Date of mailing of the international search report

0 1. 07. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

Internat. Application No.
PCT/EP 97/01899

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 431 943 A (MERCK & CO. INC.) 12 June 1991 see claims 1,9,10 ---	1,10,11
A	EP 0 004 952 A (HOECHST AG) 31 October 1979 see page 1, line 1 - line 28; claims 1,7 ---	1,10,11
A	EP 0 533 266 A (GLAXO GROUP LTD.) 24 March 1993 cited in the application see claims 1,17-20 ---	10,11
A	EP 0 533 267 A (GLAXO GROUP LTD.) 24 March 1993 cited in the application see claims 1,14-17 ---	10,11
A	EP 0 533 268 A (GLAXO GROUP LTD.) 24 March 1993 cited in the application see claims 1,17-20 -----	10,11

INTERNATIONAL SEARCH REPORT

Internat' Application No
PCT/EP 97/01899

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9611934 A	25-04-96	NONE	
WO 9619477 A	27-06-96	AU 4343396 A	10-07-96
EP 564358 A	06-10-93	FR 2689509 A	08-10-93
		AU 3559793 A	07-10-93
		CA 2093112 A	02-10-93
		JP 6287190 A	11-10-94
		JP 7084471 B	13-09-95
		NZ 247305 A	21-12-95
		US 5376661 A	27-12-94
		US 5420150 A	30-05-95
		US 5397783 A	14-03-95
		ZA 9302359 A	15-06-94
EP 635497 A	25-01-95	FR 2709306 A	03-03-95
		AU 674080 B	05-12-96
		AU 6755094 A	02-02-95
		CA 2128359 A	21-01-95
		JP 7304753 A	21-11-95
		NZ 264050 A	26-07-95
		US 5436261 A	25-07-95
		ZA 9405337 A	01-03-95
EP 431943 A	12-06-91	AU 6329794 A	21-07-94
		AU 6787390 A	13-06-91
		CA 2031633 A	09-06-91
		CN 1053613 A	07-08-91
		CN 1110685 A	25-10-95
		JP 4217960 A	07-08-92
		JP 7047576 B	24-05-95
		NZ 236315 A	27-09-94
		US 5633247 A	27-05-97
		US 5206240 A	27-04-93
EP 4952 A	31-10-79	US 4166119 A	28-08-79
		AT 372683 B	10-11-83
		CA 1132987 A	05-10-82
		JP 54145661 A	14-11-79

Internat Application No
PCT/EP 97/01899

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 533266 A	24-03-93	AU 2452992 A	25-03-93
		CA 2078506 A	19-03-93
		CN 1071922 A	12-05-93
		HU 66319 A	28-11-94
		JP 6107649 A	19-04-94
		US 5356893 A	18-10-94
		ZA 9207107 A	08-09-93

EP 533267 A	24-03-93	AU 2452892 A	25-03-93
		AU 2568792 A	27-04-93
		CA 2078507 A	19-03-93
		CN 1073430 A	23-06-93
		CZ 9400611 A	16-11-94
		WO 9306084 A	01-04-93
		FI 941261 A	17-03-94
		JP 6107637 A	19-04-94
		NO 940974 A	17-03-94
		US 5358948 A	25-10-94
		ZA 9207106 A	17-03-94

EP 533268 A	24-03-93	AP 303 A	28-01-94
		AU 656021 B	19-01-95
		AU 2453092 A	25-03-93
		CA 2078505 A	19-03-93
		CN 1071919 A	12-05-93
		HU 65608 A	28-07-94
		IL 103198 A	18-06-96
		JP 6116251 A	26-04-94
		NZ 244373 A	28-03-95
		US 5510350 A	23-04-96
		US 5340810 A	23-08-94
		ZA 9207108 A	08-09-93
		CN 1076195 A	15-09-93

